Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

teprotumumab

A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Teprotumumab binds to membrane-bound IGF-1R, preventing the binding of the natural ligand IGF-1 and the activation of PI3K/AKT signal transduction; downregulation of the PI3K/AKT survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-IGF-1 receptor human monoclonal antibody R1507
immunoglobulin G1, anti-(human insulin-like growth factor I receptor)(human monoclonal heavy chain), disulfide with human monoclonal light chain, dimer
Code name:R1507
RG1507
RO4858696-000
RV001
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search